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Glucocorticoids are used for many purposes in veterinary medicine but often come with
significant adverse effects. Polyuria and polydipsia are the most common adverse effects noted
by owners. To determine whether administration of desmopressin ameliorated the polyuria
and polydipsia, a prospective study with 7 healthy Walker Hounds was performed. Daily water
intake and urine specific gravity were measured in dogs under 4 separate conditions: no
medications, prednisolone only, prednisolone and desmopressin, and prednisolone
immediately after discontinuation of desmopressin. When compared to baseline, six out of
seven dogs became polydipsic after administration of prednisolone twice daily. When
desmopressin was administered to dogs receiving prednisolone, there was a statistically
significant decrease in water intake and sodium concentration, and a significant increase in
urine specific gravity. This suggests that desmopressin ameliorates the most significant side

effect of prednisolone noted by owners, but that hyponatremia is an important complication
associated with desmopressin.
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CHAPTER I
INTRODUCTION
Steroids, particularly prednisone and prednisolone, are used extensively in veterinary
medicine. Their use is so universal that it is difficult to identify a practitioner who is
uncomfortable prescribing them. It is important, however, to remain vigilant in prescribing these
medications as their use is not benign.
The side effects of steroids are vast and have the potential to affect almost every body
system. Some of the most well-known and commonly encountered adverse effects include
polyuria, polydipsia, and polyphagia. These are experienced by 90.4%, 88.5%, and 86.5%,
respectively, of dogs in one study (Lau et al., 2019) in which dogs were treated with high doses
of steroids for management of steroid-responsive meningitis-arteritis.
Issues such as gastrointestinal ulceration, renal and hepatic damage, and increased risk
of infection are examples of side effects that are not likely to be apparent to owners until they
are well-established. In the authors’ experience, the cost of treating these adverse effects once
they are established may be substantial enough that humane euthanasia is chosen as an
alternative to treatment.
Behavioral changes may also be seen. When the owners of 31 mixed breed dogs were
surveyed, changes such as increased aggression, increased propensity to startle or bark, and food
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guarding were reported (Notari & Mills, 2011). In a review by Lambert et. al (Lambert, Coe, Niel,
Dewey, & Sargeant, 2015), behavioral issues were cited as the first or second reason for pet dogs
being surrendered to shelters. These surrendered pets may end up being euthanized as
behavioral problems are cited as the sole reason for euthanasia in 9.6 to 17.8% of cases (Lambert
et al., 2015).
For some owners, the side effects can become so bothersome that owners report a
decrease in dogs’ quality of life. In Lau et. al, owners of dogs being treated for steroid-responsive
meningitis-arteritis were asked to rate quality of life during treatment. Owners reported that
higher prednisone doses were associated with more severe side effects. In addition, quality of
life was significantly worse during treatment compared to that during clinical resolution. For
many pet owners, this would be deemed unacceptable as domesticated dogs for whom owners
seek veterinary care are often considered members of the family.
Desmopressin acetate, an analogue of the hormone vasopressin, has been utilized in
human medicine for many specific reasons. One of these reasons is the treatment of bed wetting
in children, in which intranasal or oral administration prior to bedtime successfully prevented
enuresis in almost 90% of patients (Chiozza et al., n.d.; Del Gado et al., 2005). This drug has been
used in veterinary medicine, though primarily for the treatment of central diabetes insipidus.
Investigation into its use in reducing urine volume has not been previously investigated and may
present a solution to the issue of extreme polyuria and polydipsia experienced secondary to
prednisone therapy while allowing the pet to remain on doses that are effective for controlling
the disease for which corticosteroid therapy is indicated.
2
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CHAPTER II
LITERATURE REVIEW
Vasopressin
Vasopressin is a hormone synthesized by magnocellular neurons in the posterior
hypothalamus, also known as the neurohypophysis. One of the primary functions of
vasopressin is to regulate extracellular fluid volume by regulating renal handling of water.
Vasopressin is the key antidiuretic hormone (ADH) in all mammals. Release of vasopressin is
triggered by both hypovolemia and hypernatremia (Cuzzo, Padala, & Lappin, 2020). An increase
in plasma osmolality by as little as 1%, or a decrease in blood volume or blood pressure by 10 to
15%, is sufficient to trigger osmoreceptors in or near the hypothalamus (I. Campbell, 2011;
Nelson, 2015a). A drop in blood pressure results in a decrease in atrial pressure, leading to
decreased stretch of baroreceptors located in the carotid bodies, aorta, and lungs(I. Campbell,
2011; Nelson, 2015a). Both of these scenarios trigger the generation of vasopressin in the cell
bodies of the magnocellular neurons (I. Campbell, 2011; Nelson, 2015a).
Antidiuretic actions are mediated through V2 cyclic adenosine monophosphate (cAMP)dependent receptors on renal collecting ducts (I. Campbell, 2011; Nelson, 2015a). Vasopressin
increases the permeability of the collecting duct to water by inserting aquaporin-2 water
channels into the apical membrane of the epithelial cells lining the collecting ducts, thereby
allowing an osmotic equilibrium to form between the urine and the hypertonic medullary
4

interstitium (Nelson, 2015a). In this way, the amount of water absorbed by the collecting duct is
increased and the amount lost in the urine is decreased. Once vasopressin separates from the
V2 receptor, intracellular cAMP levels decrease and the aquaporin-2 channels are
internalized(Nelson, 2015a).
Other vasopressin receptors include V1a and V3 (or V1b), which are responsible for
vasopressin’s other functions, vasoconstrictive actions (pressor effects) and stimulation of ACTH
from the anterior pituitary, respectively (Nelson, 2015a).
Desmopressin
Desmopressin acetate (DDAVP) is a synthetic commercially available analogue of
vasopressin, with a strong affinity for V2 receptors (Del Gado et al., 2005). Desmopressin is
formed when d-arginine is substituted for l-arginine present on vasopressin, and the terminal
amino group is removed from the cysteine molecule. These modifications increase the
antidiuretic effects of vasopressin while decreasing the pressor effects (Sawyer, Acosta, &
Manning, 1974).
DDAVP has many therapeutic uses in both human and veterinary medicine, including
but not limited to the treatment of central diabetes insipidus, bed wetting in children, and von
Willebrand disease. However, desmopressin must be used with care, as hyponatremia is
recognized as a potentially serious side effect.
Hyponatremia is a well-known side effect in people receiving desmopressin for
treatment of central diabetes insipidus(Behan et al., 2015; Hossain, Ghazipura, Reddy, Rivera, &
5

Mukherjee, 2018; Stoof, Cnossen, de Maat, Leebeek, & Kruip, 2016; Wang, Lin, Huang, &
Chang, 2011). This occurs due to the retention of water in the extracellular fluid, which acts to
dilute the sodium within the bloodstream. Clinical signs are not typically encountered unless
serum sodium is less than 120mEq/L, or unless the decrease has occurred quickly (Burkitt
Creedon, 2014). Any cell that contains sodium-potassium ATPase pumps will swell as water
moves from the hypoosmolar extracellular fluid into the relatively hyperosmolar interior of the
cell (Burkitt Creedon, 2014). While this change occurs in many cells throughout the body, the
central nervous system is most sensitive. Once hyponatremia has existed for more than two to
three days, it is considered chronic and osmotically active substances such as potassium and
amino acids are extruded from cells(Dewey, 2016). Overly aggressive correction of chronic
hyponatremia then leads to axonal shrinkage and subsequent demyelination(Dewey, 2016). The
lesions of myelinolysis may not be evident for several days after correction of hyponatremia.
There is myelin loss and injury to the oligodendroglial cells in the pons, thalamus, subcortical
white matter, and cerebellum(DiBartola, 2012). Seizures, coma, or even death may occur as a
result(Burkitt Creedon, 2014).
Case reports of these severe side effects include a 6-year-old boy who experienced
generalized convulsions with unconsciousness, a tonic-clonic pattern of movements and
cyanosis on the fourth day of DDAVP therapy for nocturnal enuresis (Schwab et al., 1996). This
individual had a severe hyponatremia of 125 mmol/L at initial evaluation but this later
normalized. Though this individual required intubation and ventilation, he was extubated and

6

recovered successfully. Alternative therapy was initiated for his nocturnal enuresis. This case
highlights the risk assoiated with therapeutic use of DDAVP.
A second case report(Hossain et al., 2018) describes a 69-year-old man who presented
to the emergency department with a one month history of progressive fatigue, anorexia,
dizziness, weakness, and gait instability. This individual was being treated with desmopressin at
10 µg twice daily for central diabetes insipidus. At initial examination, serum sodium was 96
mmol/L, representing a decrease from 125 mmol/L 2.5 months prior to presentation, and also
down from 134 mmol/L when desmopressin therapy was initiated 6 months prior. Over the
course of 8 days of hospitalization, serum sodium levels stabilized between 130 and 132
mmol/L and mental status and neurologic symptoms improved. Magnetic resonance imaging
(MRI) of the brain performed 25 days after admission, however, revealed central pontine
myelinolysis which was not present on MRI on day 3 of hospitalization. The authors speculate
that despite the slow correction of hyponatremia, abrupt discontinuation of the individual’s
desmopressin may have had an adverse effect and recommend tapering the drug in future
cases.
Interestingly, reports such as these have appeared with decreasing frequency since the
1990s, likely indicating an increased knowledge and subsequent avoidance.
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Conditions Treated with Desmopressin
Diabetes insipidus
Diabetes insipidus is the disease resulting from decreased production or action of
vasopressin. Central diabetes insipidus (CDI) is the manifestation of destruction or failure of
production of the magnocellular neurons that secrete vasopressin. It can be caused by
destruction of the production sites of ADH in the hypothalamus (ie the supraoptic and
paraventricular nuclei), loss of the axons that carry it to its storage sites in the posterior
pituitary, or disruption of the ability to release ADH(Engelking, 2012; Hall, 2016; Nelson, 2015b).
In essence, any sort of damage to the brain including external trauma or destruction of neural
tissue secondary to neoplasia, infection, or disrupted blood supply(Engelking, 2012; Hall, 2016;
Nelson, 2015b) may lead to CDI. In people, CDI occurs in 26-28% of cases of moderate to severe
traumatic brain injury (Agha et al., 2004). Though this is a rare phenomenon in veterinary
medicine, it has also been reported in dogs and cats following traumatic brain injury (Foley,
Bracker, & Drellich, 2009) (F. E. Campbell & Bredhauer, 2005). Other commonly recognized
causes of CDI in veterinary medicine include neoplasia, hypothalamic or pituitary malformation,
cysts, lymphocytic hypophysitis, migration of parasites, and hypophysectomy (Nelson, 2015a).
In both human and veterinary medicine, supplementation with DDAVP is the standard of
care for CDI. It is available as tablets, injectable solution, and an intranasal spray, which is
commonly administered in the conjunctival sac of affected dogs for owner convenience. Since
CDI is rare in dogs, there is no universally accepted treatment protocol. Alterations in dose are
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often made based on the individual’s response. If treatment with DDAVP cannot be provided,
dogs with CDI may have an acceptable quality of life as long as they are provided free access to
water and access to a place to urinate.
Diabetes insipidus may also be nephrogenic in origin and is, in those cases, identified by
that qualifying adjective. Nephrogenic diabetes insipidus is a form of the disease in which there
is a deficiency or complete lack of interaction between vasopressin and its receptors on the
renal tubules(Nelson, 2015a). In veterinary medicine, nephrogenic diabetes insipidus most
often occurs secondary to other disorders (Cohen & Post, 2002), such as hyperadrenocorticism,
pyometra, pyelonephritis, and hypercalcemia. For example, in cases of hypercalcemia, diabetes
insipidus is believed to be caused by damage to ADH receptors located on the membranes of
the renal collecting ducts. Therefore, in hypercalcemia, as well as the other causes listed above,
treatment of the underlying disease is the most appropriate management option. Further
discussion of acquired nephrogenic diabetes insipidus will not be included. We will, however,
discuss some of the lesser known applications of DDAVP.
Nocturia
One of the most common uses of DDAVP in human medicine is for treatment of
nocturia, which is defined as 2 or more episodes of urination during normal sleeping hours.
Nocturia is estimated to affect 15.5% of men and 20.9% of women (Kupelian et al., 2011). A
more specific term, enuresis, refers to the transitory urinary incontinence that most frequently
affects young children before adequate control of urinary sphincters is achieved. Nocturnal
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enuresis is not exclusively a disorder of young children, and persists beyond 6 years of age in
approximately 10% of children (Del Gado et al., 2005). Pharmacologic treatment options
include imipramine, a tricyclic antidepressant (Fritz, Rockney, & Yeung, 1994), while alternative
management options include restriction of fluid intake in the hours before bedtime and the use
of an enuresis alarm (Nevéus et al., 2020). Finally, DDAVP has evolved as an effective
pharmacologic treatment option for nocturnal enuresis, and has been in use for more than 20
years (Del Gado et al., 2005).
Efficacy of DDAVP for treatment of nocturia
In a study by Chiozza and others (Chiozza et al., 1999) involving Italian children aged 5 to
17 years, intranasal administration of DDAVP was used in 5 different treatment schedules. The
first 2 groups involved administration of DDAVP at doses of 20mcg/day and 30mcg/day at
bedtime for 6 weeks. In groups 3 and 4, DDAVP was administered at 20mcg and 30mcg,
respectively, for the first two weeks. A 2-week washout period then followed, after which
group 3 received 30mcg and group 4 received 20mcg. For group 5, DDAVP was administered at
increasing dosages, from a minimum of 20mcg to a maximum of 40mcg to assess response in
relation to dose. For each group, efficacy was assessed via recording the number of nights that
passed without any involuntary urination. In the first two groups, there was a significant
decrease in the number of “wet nights”. This held true for the third and fourth groups as well.
In fact, although interruption of therapy during the 2-week washout periods lead to an increase
in the number of “wet nights,” the incidence still remained lower than that in the baseline
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periods before the study was commenced, and in the follow-up periods. There was no
significant difference between efficacy for those groups that received 20 mcg/day and those
that received 30 mcg/day. Treatment was also deemed safe, although serum electrolytes were
not monitored, as only 3 of 218 patients experienced side effects, including local irritation in 2
patients and rhinitis in 1.
Efficacy of DDAVP for treatment of enuresis was demonstrated in a second study by Del
Gado et.al, which investigated DDAVP use in either intranasal or oral forms in 541 patients.
Success was defined as resolution of enuresis within 6 months, and was achieved in 89.6% of
participants. An additional 4.4% were considered partial responders, defined as a reduction of
more than 50% but less than 90% in the number of wet nights. Urine volume was not measured
in this study, however.Only 5. 9% of the total numbers of participants experienced side effects.
Serum levels of sodium, potassium, and chloride were within respective reference ranges both
at baseline and at the end of treatment. This is an important finding because hyponatremia is
arguably the greatest risk associated with the use of DDAVP.
Von Willebrand Disease
Von Willebrand disease (vWD) is the most common inherited bleeding disorder in both
humans (Swami & Kaur, 2017) and dogs (Thomas, 1996), and was first described by Dr. Eric von
Willebrand in 1926. The affected individual was a 13-year-old female in which excessive
hemorrhage during a menstrual period lead to her demise (von Willebrand, 1926). vWD results
from deficient or defective plasma levels of von Willebrand factor (vWF), which is produced by
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megakaryocytes and endothelial cells. In endothelial cells, vWF is stored in cytoplasmic granules
known as Weibal-Palade bodies and in the alpha granules of platelets. The disease exists as
three different types. Type 1 is the most common in man (Swami & Kaur, 2017) and dogs
(Callan, Gigers, & Catalfamo, 2005), and is characterized by a decrease in the concentration of
vWF to <50% of reference ranges. vWD affects approximately half of Doberman Pinschers, and
has been reported in more than seventy other breeds (Callan et al., 2005). These individuals
may be asymptomatic or have only mild signs of mucocutaneous bleeding. In type 2 vWD, there
is a qualitative deficiency of vWF activity.
DDAVP for von Willebrand disease
In humans with vWD, administration of desmopressin results in an increase in both
factor 8 and vWF. This is proposed to be due to the release of vWF from endothelial cell
Weibel-Palade bodies. A series of studies by Mannucci et al. revealed a 2- to 5-fold increase
with DDAVP in vWF in normal adults and those with type-1 vWD (Mannucci, Canciani, Rota, &
Donovan, 1981; Mannucci, Pareti, Ruggeri, & Capitanio, 1977). Another study performed at
Harvard Medical School supported these results, and also determined that levels of vWF were
highest at 60 minutes post-DDAVP injection(Guddati, Rosovsky, Van Cott, & Kuter, 2019). In
dogs, however, there was no statistically significant increase in vWF after desmopressin
administration in healthy dogs or Doberman Pinschers with von Willebrand’s disease (Giger &
Dodds, 1989). In addition, there was no substantial change in factor 8 activity up to 6 hours
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after subcutaneous DDAVP administration (Mansell & Parry, 1991). Therefore, the therapeutic
use of DDAVP in canine vWD is rather limited.
This finding was echoed in a 2002 study performed by the University of Pennsylvania in
which administration of DDAVP at a dose of 1 µg/kg subcutaneously did not elevate levels of
vWF to within reference range in any of the sixteen dogs tested. In addition, when hemostasis
was evaluated in this same group of dogs by buccal mucosal bleeding time and PFA-100®,
although there was a significant decrease in both parameters, neither of which resulted in
values within reference range (Callan & Giger, 2002). This suggests that procedures with the
potential to cause hemorrhage would not be safe in DDAVP-treated individuals with vWD.
Mammary carcinoma
There was once interest in DDAVP as supplemental treatment for mammary carcinoma
when it was determined that DDAVP inhibited lung colonization by aggressive carcinoma cells in
vitro (Alonso, Skilton, Farïas, Bal De Kier Joffé, & Gomez, 1999). In an attempt to evaluate these
results in canine veterinary medicine, DDAVP was administered in a similar fashion
(intravenously 30 minutes prior to and 24 hours following surgery) to bitches undergoing
surgical resection of stage 3 or 4 mammary gland tumors(Hermo et al., 2008). When mammary
carcinomas were evaluated separately, both median disease-free time and overall survival
times were >600 days in the DDAVP versus 97 days and 351 days for the placebo group,
respectively. Unfortunately, these findings were contradicted in the most recent study to
address this question. When 24 dogs with mammary carcinomas were split into equal groups of
13

12 each, there was no difference in time to metastasis or overall survival between those who
received DDAVP at 3mcg/kg subcutaneously as part of their anesthestic pre-medication and
then again 24 hours post-operatively, and those who received a placebo(Sorenmo, Durham,
Evans, Scavello, & Stefanovski, 2020)
Corticosteroids
Steroid hormones are produced by the three layers of the adrenal cortex: the zona
glomerulosa, zona fasciculata, and zona reticularis. Aldosterone is the main product of the zona
glomerulosa, although it may also produce corticosterone (I. Campbell, 2011). Cortisol is the
main product of the zona fasciculata. Androgens, mainly dehydroepiandrosterone and
andreostenedione, are the main products of the innermost zona reticularis. Cholesterol is the
main precursor of all adrenal steroids and is provided to the adrenal gland from the source of
low-density lipoproteins via receptors located on adrenal tissue (Arlt & Stewart, 2005).
Exogenous glucocorticoid therapy is widely used in both human and veterinary
medicine. Glucocorticoid use primarily falls into one of three modalities: anti-inflammatory,
immunosuppressive, and replacement therapy in the case of hypoadrenocorticism.
Glucocorticoids act through intracellular receptors of the steroid receptor superfamily and
through membrane-bound receptors that are located on most cells in the body (Thacker, 2010).
Glucocorticoids exert anti-inflammatory activity by reducing the production of several
interleukins, including IL-3, IL-4, IL-5, and IL-10, tumor necrosis factor alpha, and granulocyte
monocyte colony stimulating factor (Thacker, 2010).When used at immunosuppressive doses,
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glucocorticoids also decrease phagocytosis and IL-1 production by macrophages, decrease
antigen presentation, and reduce extravasation of white blood cells, including the margination
and migration of neutrophils (Viviano, 2013).
Because of these varied mechanisms, the use of steroids has become the mainstay of
treatment for many immune-mediated disorders, including primary immune-mediated anemia,
primary immune-mediated thrombocytopenia, idiopathic immune-mediated polyarthritis, and
steroid-responsive meningitis-arteritis. However, there are drawbacks associated with this
treatment, including side effects such as polyuria and polydipsia, which are observed in
approximately 90% of dogs (Lau et al., 2019).
Although it is common for other immunosuppressive agents to be used concurrently
with glucocorticoids in order to allow for more rapid tapering of glucocorticoid doses,
considerations such as the high cost of modified cyclosporine (approx. $200 per month for a
dog weighing 25 kilograms), the gastrointestinal side effects of mycophenolate, and the need
for monitoring of liver enzymes with azathioprine can make the use of secondary
immunosuppressive medications impractical and expensive. The cost of DDAVP is $50-100 for
five milliliters of the 0.01% intranasal preparation. If dosed similarly to the doses used in our
study, this amount would be sufficient to treat a 25kg dog for over 3 months. In addition, if a
future study reveals that oral DDAVP is also efficacious in dogs, tablets are available at an even
lower cost.
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Steroid side effects continue to be an issue with pets and pet owners. For some, steroid
side effects may culminate in pets being surrendered to shelters and may end up with
euthanasia, as disease accounts for 21 to 63% of shelter euthanasias (Lambert, Coe, Niel,
Dewey, & Sargeant, 2015).
Understanding the mechanism of polyuria and polydipsia with glucocorticoid is
paramount to trying to dampen it. Proposed mechanisms include primary polydipsia,
antagonism of the anti-diuretic hormone (ADH) receptor (Nelson, 2015a; Reusch, 2015), and
inhibition of ADH release from the pituitary(Reusch, 2015). This last theory is supported by
research performed by Papanek and Raff(Papanek & Raff, 1994) in which 5 healthy dogs
received continuous infusions of either hypertonic saline or cortisol in sequential protocols.
Arterial blood samples were obtained to measure hematocrit, plasma sodium, plasma
potassium proteins, vasopression, cortisol, and osmolality. The results indicated that infusion of
cortisol caused a significantly decreased vasopressin concentration on days 4 and 7 when
compared to the control period. The authors speculate that cortisol directly inhibits vasopressin
release or suppression of vasopressin from magnocellular cells, similar to the case in central
diabetes insipidus. They also speculate that cortisol may induce changes at the osmoreceptor.
Due to the success of DDAVP in reducing urine volume in nocturia and the other
indications described above, my thesis research was designed to determine whether its use
would be efficacious in reducing polyuria and polydipsia in dogs being treated with
corticosteroids. If the theory of Papanek and Raff holds true and there is corticosteroid-induced
inhibition of vasopressin release or synthesis, we would expect DDAVP to be effective. We
16

specifically investigated the use of subcutaneous administration of DDAVP. Although DDAVP is
available in both tablet forms and as eye drops for subconjunctival application, and these are
likely to be more convenient for owners, tablet forms were purposefilly avoided in this study
due to the fact that oral hormones in dogs typically have poor bioavailability compared to
bioavailabity in people. In regards to ocular administration, it has been my mentors’ experience
that subcutaneous administration leads to more consistent absorption when compared to the
subconjunctival route.
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CHAPTER III
EFFECTS OF DESMOPRESSIN ACETATE ADMINISTRATION IN HEALTHY DOGS RECEIVING
PREDNISOLONE
Introduction
Glucocorticoids, including prednisolone, are used in the treatment of many diseases in
veterinary medicine (Elkholly et al., 2020)(Blois & Matthews, 2017)(Archer, 2017). These
include, but are not limited to, dermatologic diseases in which anti-inflammatory effects are
beneficial in providing patient comfort, as well as immune-mediated diseases in which higher
doses are used for immunosuppression (Reusch, 2015)(Archer, 2017). Anti-inflammatory
activity is mediated mainly through reducing the production of several interleukins. When used
at immunosuppressive doses, glucocorticoids exert their activity by decreasing phagocytosis
and IL-1 production by macrophages, decreasing antigen presentation, and reducing
extravasation of white blood cells (Viviano, 2013)(Whitley & Day, 2011)(Reusch, 2015)(Archer,
2017). Like any drug, however, glucocorticoids have adverse effects, including polyphagia,
muscle wasting, and, perhaps most bothersome to owners, polyuria and polydipsia (Archer,
2017; Elkholly et al., 2020; Goggs, 2020; Whitley & Day, 2011). For many, these may become a
quality of life issue for both owners and their pets (Lau et al., 2019). Because these side effects
are dose-related, owners may independently decrease dosages or discontinue medications in
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order to alleviate side effects. Doing so, however, can lead to a lack of treatment response or
disease relapse.
Proposed mechanisms for the polyuria and polydipsia induced by glucocorticoids
include primary polydipsia and antagonism of the anti-diuretic hormone (ADH) receptor
(Nelson, 2003)(Reusch, 2015). ADH, or arginine vasopressin, is a peptide hormone secreted by
the posterior pituitary gland to maintain homeostasis regarding extracellular fluid osmolality
and blood pressure and volume (Nelson, 2015). Its main action is to promote reabsorption of
free water in the collecting ducts of the kidneys. Following binding of ADH to the V2 receptors
on the basolateral membrane of renal tubular cells in the collecting duct epithelia, water
channels (aquaporin-2) are inserted into the apical membrane, allowing free water to enter the
cell and then diffuse down its concentration gradient into the medullary interstitium. The net
effects include free water being extracted from the glomerular filtrate, resulting in a decrease
in urine volume and an increase in urine concentration.
Desmopressin, a synthetic analogue of ADH, has been used to treat central diabetes
insipidus, a disease in which ADH production is deficient (Nelson, 2015). It has also been used
successfully in the treatment of nocturia in children (VANDE WALLE et al., 2006), most often by
oral administration sixty minutes prior to bedtime (Nevéus et al., 2020). The efficacy is often
evident immediately, and approximately 2/3 of children will have an intermediate to full
response (Robson, Nørgaard, & Leung, 1996). To the authors’ knowledge, however, its use as an
adjunctive treatment to decrease polyuria and polydipsia in dogs being treated with exogenous
glucocorticoids has not yet been explored.
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The aim of this study was to determine whether concurrent administration of
desmopressin during prednisolone therapy would lead to a decrease in water consumption and
increase in urine specific gravity. A secondary aim was to assess the safety of administration of
desmopressin, specifically in relation to serum sodium concentrations.
Materials and methods
Study design
Experiment and animal care protocols were approved by Mississippi State University
Institutional Animal Care and Use Committee. Mississippi State University is accredited by the
Association for Assessment and Accreditation of Laboratory Animal Care.
Seven adult Walker hounds, members of a healthy research dog colony, underwent
screening prior to drug administration via a full physical exam as well as a CBC, chemistry, and
urinalysis; no significant clinical abnormalities were identified. In one dog, a urine specific
gravity (USG) rather than a full urinalysis was performed due to insufficient sample quantity.
Water intake per day and USG once daily (at noon) were measured for each dog. To measure
the water intake per day, a large water bowl (secured to the chain linked walls of the run) was
filled with a known amount of water measured with a large, graduated cylinder. Each morning,
the water left in the bowl was measured to determine the amount drunk in the previous 24
hours, and the bowl refilled with a known amount of water. In addition to urinating in their
kennels and while walked in the morning and evening, the dogs were walked within one hour of
noon daily, and a body weight and free catch urine sample collected. If urine could not be
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collected at this time, it was obtained either during an addition walk prior to 5 pm, or from a
sample collected from the floor in the dog’s run. The USG was measured on these noon
samples with a standard refractometer (Reichert Vet 360). These procedures were followed for
5 days prior to administration of any medication to the dogs. This period was considered the
control (C) period.
Treatment
Starting on day 6, prednisolone (PrednisTab, Lloyd, Inc. of Iowa) was administered to
each dog as 0.5 mg/kg per os every 12 hours, for a total daily dose of 1 mg/kg/day. Medication
administration occurred in the morning at approximately 7am and in the evening at
approximately 7pm. Daily water intake and USG were then measured as described for days 1-5.
This was the prednisolone (P) treatment period.
Blood was collected via jugular venipuncture into red top tubes for measurement of
serum sodium, starting on day 3 of prednisolone treatment and performed every 72 hours
thereafter to ensure significant hyponatremia did not develop.
After 7 days of oral prednisolone therapy, desmopressin acetate (Sun Pharma, Cranbury,
New Jersey) administration was started in 6 out of 7 dogs, at a dose of 5 mcg every 12 hours
subcutaneously for 5 days. This was the prednisolone plus desmopressin treatment period (PD).
During this time period, daily water intake as well as daily USG were measured as previously
described.
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After finishing the desmopressin treatment, daily prednisolone therapy was continued
and daily water intake as well as daily USG were measured as previously prescribed for 5
additional days. This was the prednisolone after desmopressin treatment period (PAD).
Statistical methods
Descriptive and inferential statistics were performed using commercially available
statistic software (SAS for Windows v. 9.4, SAS Institute, Inc. Cary, NC). For each dog, a mean
urine specific gravity (USG) and mean water intake was calculated for each treatment period,
using the values for the last three days of each treatment. Sodium concentration was measured
once for each dog during each treatment period. The effect of treatment on the mean value of
USG and water intake, and sodium concentration was assessed using a generalized linear mixed
model within PROC MIXED. For each model, patient I.D. was considered a random variable.
Inspection of conditional residuals was used to assess if model assumptions were met. The
model of water intake did not meet the assumptions of homoscedasticity and normality of the
residuals, so the data for outcome water intake was log 10 transformed. For each model, least
square means were calculated for each level of treatment, and the following sequential
comparisons among treatment levels were made: control (C) vs prednisolone (P), prednisolone
(P) vs prednisolone plus desmopressin (PD), prednisolone plus desmopressin (PD) vs
prednisolone after desmopressin (PAD), prednisolone (P) vs prednisolone after desmopressin
(PAD), and control (C) vs prednisolone plus desmopressin (PD). The least squares means are
presented in Table 1. Dog body weight at the beginning of the treatment period, compared to
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body weight at the end of the treatment period, was evaluated using a paired sample t-test in
PROC TTEST. An alpha level of 0.05 was used to determine statistical significance.
Results
Baseline characteristics of study subjects
Seven dogs were initially enrolled. All received prednisolone as described. Six of seven
dogs received desmopressin injections as described. Desmopressin was withheld from one dog
because this individual dog did not become polydipsic or polyuric during the prednisolone
treatment period. Her 3 day mean water intake was 56 mL/kg/day, and her urine remained
concentrated with a 3-day mean specific gravity of 1.033. Therefore, concern for development
of significant free water overload and hyponatremia following administration of desmopressin
precluded safe administration. Data from this dog was excluded from analysis of serum sodium
levels.
Effect of treatment on USG and water intake
Administration of desmopressin significantly decreased and increased water intake and
urine specific gravity. Treatment least squares means and their standard errors for each of the
outcomes are presented in Table 1. Treatment was significantly associated with USG (p<0.001),
log10 water intake (p<0.001), and sodium concentration (p<0.001). Sequential comparisons of
least squares mean estimates of treatment levels were performed for each outcome. When
compared to the previous treatment, each dog had a significant change in USG (Figure 3.1). In
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the model of USG, treatment level comparisons of least square means were as follows: C vs P
(p=0.014), P vs PD (p<0.001), PD vs PAD (p<0.001), P vs PAD (p=0.479), and C vs PD (p=0.022). In
the model of logH2Oml/kg, treatment level comparisons of least square means were as follows:
C vs P (p<0.001), P vs. PD (p=0.007), PD vs PAD (p<0.001), P vs PAD (p=0.037), and C vs PD
(p=0.702) (Figure 3.2).
Effect of treatment on serum sodium concentrations
No significant difference was detected when sodium concentration prior to treatment
(C) were compared to those following administration of prednisolone (P). There was a
significant decrease in serum sodium after administration of desmopressin (PD) and a
significant increase 36 hours after desmopressin administration was discontinued (PAD), while
the dogs were still receiving prednisolone (Figure 3.3). In the model of sodium concentration,
treatment level comparisons of least square means were as follows: C vs P (p=0.985), P vs. PD
(p=0.001), PD vs PAD (p<0.001), P vs PAD (p=0.405), and C vs PD (p=0.001).
Effect of treatment on weight
Dog weight at the start of the treatment period (mean = 27.96, std. dev. = 5.85) was
greater than dog weight (mean = 26.39, std. dev. = 5.79) at the end of the treatment period
(p<0.001).

29

Discussion
Results of this study indicate that administration of desmopressin significantly
decreased the polyuria and polydipsia exhibited by dogs during prednisolone administration.
This supports the theorythat prednisolone causes polyuria and polydipsia by either inhibiting
release of ADH, or antagonizing the action of ADH in the renal tubule.
There was a large amount of individual variation in both the polydipsia induced by
prednisolone (P) and the improvement (decreased water consumption) in response to
desmopressin (PD). Of the six dogs who were treated with desmopressin, the mean decrease in
water consumption was 52.1 mL/kg/day (median: 32.5). This did vary widely, however, from
17.2 mL/kg/day to 177.3 mL/kg/day. Additionally, desmopressin was never administered to one
of the seven dogs due to a lack of polyuria and polydipsia after prednisolone administration.
This situation may represent the 10% of dogs with hyperadrenocorticism that are not polyuric
or polydipsic (Perez-Alenza & Melian, 2017), despite these being considered the main clinical
signs associated with the disease.
In all but one dog, the USG was higher in dogs treated with desmopressin when the
control (C--no treatment) period was compared to the PD group, and the comparison of least
square means showed a significant difference in C vs PD (p=0.022). There was also a significant
decrease in Na concentration in the dogs receiving prednisolone when desmopressin was
added as a treatment (P vs PD, p=0.001), and the least square means comparison of Na
concentration between C and PD showed that there was a significant decrease in the PD group
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(p=0.001). Additionally, the least square means of logH2Oml/kg was not different between C
and PD (p=0.702). This means that, when compared to the control period, desmopressin
administration normalized the increased water intake caused by prednisolone, and caused the
urine to be concentrated excessively compared to control, causing free water retention and a
decrease in Na concentration. This is likely due to the renal free water resorption caused by the
desmopressin and unrestricted water intake in the dogs. This confirms that the polyuria and
polydipsia caused by prednisone is due to inhibition of pituitary secretion or renal tubular
action of ADH. A lower dose of desmopressin may have prevented or lessened the decrease in
sodium.
The authors have heard (anecdotally) primary polydipsia as an explanation for the cause
of PU/PD by prednisolone. Although water intake was not different between the C and PD
groups, the Na concentration decreased. In normal dogs, the thirst response should decrease
with hyponatremia (and subsequent hypoosmolality), but it did not, so primary polydipsia
cannot be ruled out. However, in people treated with desmopressin with diabetes insipidus,
hyponatremia is the most common complication. One explanation in people, which may also
apply in dogs, is that fluid intake is social and habitual, rather than thirst driven, so fluid intake
may be in excess of physiological needs, resulting in hyponatremia (Behan et al., 2015).
The magnitude of decrease in Na concentrations in some of the dogs in the PD group
was clinically significant. Although the least square means Na concentration in the PD group
was 136 mEq/L, one dog decreased from 142 mEq/L to 131 mEq/L. This decrease took place
over a 3-day period. Acute decreases in Na can be detrimental, resulting in seizures and
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cerebral edema (DiBartola, 2012). In severely hypernatremic dogs, it is recommended to
decrease the Na concentration by no more than 0.5 to 1.0 mEq/L/hr) to prevent neurologic
complications (Silverstein & Hopper, 2015). No clinical signs associated with the Na decrease
were noted in any of the dogs in our study. Unfortunately, concurrent desmopressin and
prednisolone therapy was only continued for 5 days, so it is difficult to know whether the Na
concentrations would continue to decrease more over a longer period of time. Additionally,
one dose of desmopressin (5 mcg/dog) was used for all dogs. A lower dose is likely to have
resulted in less clinically significant hyponatremia, but this was not studied. Although water
restriction would also lessen the severity of hyponatremia, this was not attempted, and is not
recommended in clinical patients due to potential complications associated with overrestriction. In people with diabetes insipidus and hyponatremia associated with desmopressin
use, one recommendation is to skip one dose of desmopressin per week to allow for aquaresis
(Behan et al., 2015).
In this study, prednisolone was chosen as the glucocorticoid administered at a dosage
of 1mg/kg/day, representing what many practitioners use as the high end of the antiinflammatory dosage for prednisolone. Administration of higher prednisolone dosages would
be expected to result in the same side effects but with increased magnitude. Desmopressin was
administered subcutaneously rather than orally or conjunctivally to ensure consistent
absorption, as the experience of two of the authors has been that patients with central
diabetes insipidus that do not respond to ocular administration of desmopressin may respond
to subcutaneous injections.
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Our study had several limitations. Only one breed of dog, the Walker Hound, was
utilized; other breeds may respond differently to prednisolone. However, significant variation
was noted, even within this breed. Although urine collection was attempted around noon each
day, it was not successful in each individual dog and urine samples obtained within a 6 hour
window was used in the statistical analysis. Cystocentesis would have allowed more consistency
regarding timing of urine collection, but was not pursued due to concerns posed by IACUC
regarding daily cystocenteses.
Another weakness is that water intake was not measured after prednisolone was
discontinued. Given that the water intake increased following discontinuation of desmopressin
while the dogs were still on prednisolone, even though it wasn’t a statistically significant
increase, it would have been interesting to note if water intake decreased back to baseline
values after discontinuation of prednisolone. Unfortunately, this data was not obtained, but
should be considered for similar studies in the future.
This is the first study to document a decrease in water intake and increase in urine
specific gravity when subcutaneous desmopressin was administered to dogs receiving
prednisolone. Sodium concentration also decreased in these dogs. Future studies should
include different routes of administration (conjunctival and/or oral) of desmopressin, and
adjustment of desmopressin dose based on sodium concentration.
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Table 3.1

Treatment least squares means ± standard errors for urine specific gravity, log10
water intake, and sodium concentration.
Sodium

Treatment

Urine Specific
Gravity

Log10 Water
Intake (ml/kg)

Control

1.034 ± 0.0038

1.59 ± 0.058

143.4 ± 1.13

Prednisone

1.020 ± 0.0038

1.93 ± 0.058

142.9 ± 1.13

Prednisone plus
Desmopressin

1.047 ± 0.004

1.67 ± 0.062

136.2 ± 1.13

Prednisone after
Desmopressin

1.015 ± 0.004

2.14 ± 0.062

145.2 ± 1.13

Figure 3.1

(mEq/L)

Box and whisker plot displaying descriptive statistics for urine specific gravity
(USG) for the means of dogs during each phase of treatment. Plot displays
minimum, 1st quartile, median, mean (Δ), 3rd quartile, and maximum values.
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Figure 3.2

Box and whisker plot displaying descriptive statistics for log10 H2O intake for
dogs during each phase of treatment. Plot displays minimum, 1st quartile,
median, mean (Δ), 3rd quartile, and maximum values.

Figure 3.3

Box and whisker plot displaying descriptive statistics of blood sodium
concentration during each phase of treatment. Plot displays minimum, 1st
quartile, median, mean (Δ), 3rd quartile, and maximum values.
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CHAPTER IV
CONCLUSION
The results of the research investigation discussed in this thesis revealed that the
subcutaneous administration of desmopressin acetate at a dose of 5mcg per patient was
effective in reducing water intake and increasing urine specific gravity in a small group of dogs
that were also administered prednisolone at an anti-inflammatory dose. Subcutaneous
administration of desmopressin appeared well-tolerated in the dogs in this study. Twenty-five
gauge needles were used, and the small needle gauge likely contributed to patient comfort. It
would be reasonable to dispense U-100 insulin syringes to owners to ensure adequate dosing. A
tutorial in injection administration could be performed similar to that utilized for owners of
diabetic pets.
Concessions such as these will likely enable owners to manage the most common side
effects of prednisone and prednisolone, namely polyuria, polydipsia (PU/PD), and polyphagia,
while maintaining dogs on glucocorticoid doses that are appropriate for the underlying disease
process. It has been our clinical experience that owners will sometimes discontinue
glucocorticoids due to excessive PU/PD, without first consulting the clinician, and the cessation
of steroids has resulted in exacerbation of the underlying condition, and even death. If the
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owner is aware that there is a simple way to decrease the degree of PU/PD whilst maintaining
the beneficial effects of glucocorticoids, these situations may be prevented in the future.
Other options that may decrease PU/PD include use of dexamethasone or
methylprednisolone, due to reduced mineralocorticoid activity in comparison to prednisone or
prednisolone (Reusch, 2015). Methylprednisolone is however considerably more expensive
than prednisone or prednisolone, and dexamethasone may be more ulcerogenic. As
glucocorticoids are considered superior to other immunosuppressives in rapidity of onset of
action, and sometimes in efficacy, the ability to use prednisolone could improve chances of
remission and/or reduce reliance on other immunosuppressive drugs such as modified
cyclosporine, azathioprine, mycophenolate, and leflunomide. In some cases, the cost of the
aforementioned medications or the required monitoring makes their use problematic for
owners.
In contrast, desmopressin is relatively affordable and available in multiple formulations,
including oral tablets, nasal sprays, and solutions for injection. Any of these can be obtained
from a local human pharmacy, or from a compounding pharmacy. The intranasal preparation of
desmopressin acetate, in particular, is considered safe for subcutaneous administration after
it’s placed in a sterile multi-use vial after being filtered through a bacteriostatic filter(Mansell &
Parry, 1991; Nichols, 2000), and a 90-day supply can be purchased for approximately $50-100
with the use of pharmacy discount programs. These forms of desmopressin can also be
purchased through compounding pharmacies such as Wedgewood Veterinary Pharmacy. On
the Wedgewood site, the cost of solutions for injection is markedly lower than commercially
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available injectable (ie. 5mL of 0.01% solution for $58) DDAVP, but similar to the cost of the
intranasal solution available commercially which is suitable for subcutaneous administration.
The compounding pharmacy also has oral liquids available for pets whom may not tolerate
tablets, injections, or eye drops. Of course, additional studies using these various formulations
would be necessary to ensure the results are similar to those obtained with commercially
available formulations.
The most significant drawback to using desmopressin is the potential to cause
hyponatremia. Because there was significant drop in serum sodium during desmopressin
administration in our study, use in clinical patients would require frequent monitoring of
electrolytes. This may represent a hinderance to some owners. It is likely, however, that once a
dose is administered for a certain period of time, the frequency of bloodwork to monitor
electrolytes could be decreased. Further studies to explore this are indicated in order to guide
clinicians in their decision-making.
Similar to desoxycorticosterone pivalate use for mineralocorticoid supplementation in
hypoadrenocorticism, desmopressin dose titration “to effect” may be possible. This could
mitigate the potential side effects of hyponatremia. Additional studies with varying doses of
desmopressin would provide helpful clinical insight and guidance.
There is a vast potential for further study in this field. Subcutaneous administration of
DDAVP was used due to perceived improved absorption versus ocular or oral administration.
Ocular and oral administration would undoubtedly be easier for owners. Thus, future studies

40

should evaluate these routes. Although DDAVP would be expected to have similar effects when
used with different glucocorticoids, this is another potential are of study. Lastly, this study was
performed in laboratory dogs under controlled conditions. The most clinically relevant followup study would evaluate the use of desmopressin in clinical patients receiving prednisolone or
other glucocorticoids for glucocorticoid-responsive conditions.
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